Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b.
作者信息
Mesa Ruben, Yacoub Abdulraheem, Tashi Tsewang, Chai-Ho Wanxing, Yoon Chang Ho, Mascarenhas John
机构信息
Levine Cancer Institute, 1021 Morehead Medical Drive, Suite 3100, Charlotte, NC, 28204, USA.
Wake Forest University School of Medicine, 475 Vine Street, Winston-Salem, NC, 27101, USA.
出版信息
Ann Hematol. 2025 Apr;104(4):2571-2573. doi: 10.1007/s00277-025-06331-z. Epub 2025 Apr 3.
Abstract
摘要
相似文献
1
Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b.应对聚乙二醇化干扰素α-2a短缺：将患者转换为聚乙二醇化干扰素α-2b的实用指南。
Ann Hematol. 2025 Apr;104(4):2571-2573. doi: 10.1007/s00277-025-06331-z. Epub 2025 Apr 3.
2
Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.新型长效聚乙二醇干扰素 alfa-2b：I 期临床试验中的药代动力学、药效学和安全性。
Br J Clin Pharmacol. 2022 May;88(5):2396-2407. doi: 10.1111/bcp.15176. Epub 2021 Dec 28.
3
Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.罗氏干扰素 alfa-2b 每两周给药一次，用于治疗基因型 2 慢性丙型肝炎患者。
J Formos Med Assoc. 2021 Mar;120(3):956-964. doi: 10.1016/j.jfma.2020.09.018. Epub 2020 Oct 16.
4
Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects.新型长效聚乙二醇干扰素 alfa-2b 在健康中国受试者中的药代动力学和药效学。
Adv Ther. 2021 Sep;38(9):4756-4770. doi: 10.1007/s12325-021-01863-y. Epub 2021 Jul 30.
5
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.聚乙二醇干扰素α-2b或α-2a联合利巴韦林用于治疗丙型肝炎感染。
N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22.
6
The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study.聚乙二醇化干扰素α-2a与聚乙二醇化干扰素α-2b治疗初治慢性丙型肝炎基因4型患者的疗效比较：一项埃及单中心研究
Hepat Mon. 2013 May 28;13(5):e10069. doi: 10.5812/hepatmon.10069. Print 2013 May.
7
The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.聚乙二醇干扰素α和利巴韦林治疗儿童和青少年慢性丙型肝炎的临床疗效及成本效益：系统评价与经济学评估
Health Technol Assess. 2014 Oct;18(65):i-xxii, 1-202. doi: 10.3310/hta18650.
8
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.每 2 周使用罗匹尼罗干扰素 alfa-2b 作为新型聚乙二醇干扰素治疗慢性乙型肝炎患者。
Hepatol Int. 2020 Dec;14(6):997-1008. doi: 10.1007/s12072-020-10098-y. Epub 2020 Oct 24.
9
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.西美瑞韦联合聚乙二醇干扰素 α-2a 或 -2b 加利巴韦林治疗初治慢性丙型肝炎病毒基因 1 型感染患者（QUEST-2）：一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2014 Aug 2;384(9941):414-26. doi: 10.1016/S0140-6736(14)60538-9. Epub 2014 Jun 4.
10
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).一项比较聚乙二醇干扰素α-2b与聚乙二醇干扰素α-2a对慢性丙型肝炎患者的药代动力学、药效学及抗病毒作用的随机试验（COMPARE）。
J Hepatol. 2006 Aug;45(2):204-13. doi: 10.1016/j.jhep.2006.03.008. Epub 2006 Apr 18.
本文引用的文献
1
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.聚乙二醇干扰素α-2b的一种替代给药策略可能有助于改善骨髓增殖性肿瘤的治疗结果：既往及正在进行的研究概述与未来展望
Front Oncol. 2023 Jan 19;13:1109866. doi: 10.3389/fonc.2023.1109866. eCollection 2023.
2
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).在接受聚乙二醇化干扰素α-2a（派罗欣）治疗后，使用罗培戈干扰素α-2b（贝丝瑞美）治疗真性红细胞增多症和原发性血小板增多症的真实世界经验。
Leuk Res Rep. 2022 Dec 16;19:100360. doi: 10.1016/j.lrr.2022.100360. eCollection 2023.
3
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.聚乙二醇干扰素α-2b对比真性红细胞增多症标准疗法（PROUD-PV和CONTINUATION-PV）：一项随机、非劣效性3期试验及其扩展研究。
Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31.
4
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.聚乙二醇干扰素α-2a（40kD）[派罗欣]与未修饰的干扰素α-2a[罗扰素]相比，可改善慢性丙型肝炎患者的健康相关生活质量结局。
Pharmacoeconomics. 2003;21(5):341-9. doi: 10.2165/00019053-200321050-00005.
5
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.聚乙二醇干扰素α-2a用于慢性丙型肝炎合并肝硬化患者
N Engl J Med. 2000 Dec 7;343(23):1673-80. doi: 10.1056/NEJM200012073432302.
6
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.干扰素α-2b单独或联合利巴韦林作为慢性丙型肝炎的初始治疗。肝炎介入治疗组。
N Engl J Med. 1998 Nov 19;339(21):1485-92. doi: 10.1056/NEJM199811193392101.
Zotero 插件